Stoke Therapeutics, Inc. Common Stock (STOK) Stock Price

STOKStock

$24.17−29.27%52W

Market Cap$1.56B

P/E—

PEG Ratio—

Div yield—

Beta1.37

STOK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-42.50%

Price vs S&P 500 (4W)-12.51%

VGM Score29.15

P/CF (Annual)34.21x

Book Value / Share (Quarterly)$5.54

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)145.85%

Cash Flow / Share (Quarterly)$-2.90

Price vs S&P 500 (YTD)-35.78%

Net Profit Margin (TTM)-753.60%

EPS (TTM)$-3.36

10-Day Avg Trading Volume0.81M

EPS Excl Extra (TTM)$-3.36

EPS (Annual)$-0.12

ROI (Annual)-1.95%

Net Profit Margin (5Y Avg)-2289.09%

Cash / Share (Quarterly)$4.69

P/E Basic Excl Extra (TTM)46.10x

Revenue Growth QoQ (YoY)-32.51%

ROA (Last FY)-1.65%

Revenue Growth TTM (YoY)-86.20%

EBITD / Share (TTM)$-3.59

ROE (5Y Avg)-40.10%

Operating Margin (TTM)-809.69%

Cash Flow / Share (Annual)$0.76

P/B Ratio4.51x

P/B Ratio (Quarterly)5.90x

Net Income / Employee (Annual)$-40,500

EV / Revenue (TTM)52.54x

ROA (TTM)-51.46%

EV / EBITDA (TTM)50.43x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)7.34x

3-Month Avg Trading Volume0.90M

52-Week Price Return-29.27%

EV / Free Cash Flow (Annual)32.27x

P/E Incl Extra (TTM)46.10x

Revenue / Employee (TTM)$162,300

Tangible BV / Share (Quarterly)$3.91

P/S Ratio (Annual)8.46x

Asset Turnover (Annual)0.44x

52-Week High$40.22

Operating Margin (5Y Avg)-2353.28%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-8.59%

26-Week Price Return-32.60%

Quick Ratio (Annual)5.13x

13-Week Price Return-16.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.69x

Enterprise Value$1.45B

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-5.21%

Revenue / Employee (Annual)$1,084,800

Pretax Margin (Annual)-3.73%

Cash / Share (Annual)$4.83

3-Month Return Std Dev47.55%

Net Income / Employee (TTM)$-1,223,000

ROE (Last FY)-1.95%

EPS Basic Excl Extra (Annual)$-0.12

Receivables Turnover (TTM)37.67x

EV / Free Cash Flow (TTM)43.72x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.36

Receivables Turnover (Annual)34.46x

ROI (TTM)-59.36%

P/S Ratio (TTM)56.53x

Pretax Margin (5Y Avg)-2289.09%

Revenue / Share (Annual)$3.11

Tangible BV / Share (Annual)$4.69

Forward P/E3939.76x

Price vs S&P 500 (52W)-44.80%

P/E Ratio (TTM)46.10x

Year-to-Date Return-23.85%

5-Day Price Return0.08%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-31.13%

Net Profit Margin (Annual)-3.73%

Month-to-Date Return-7.04%

Cash Flow / Share (TTM)$-2.37

EBITD / Share (Annual)$-0.32

Operating Margin (Annual)-11.16%

P/CF (TTM)44.93x

ROI (5Y Avg)-40.10%

P/E Excl Extra (TTM)46.10x

EPS Basic Excl Extra (TTM)$-3.36

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)5.14x

Pretax Margin (TTM)-758.23%

Book Value / Share (Annual)$5.98

Price vs S&P 500 (13W)-19.48%

Beta1.37x

P/FCF (Annual)34.72x

Revenue / Share (TTM)$0.42

ROE (TTM)-59.36%

52-Week Low$20.32

vGradeD

gGradeF

mGradeC

vgmGradeD

STOK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$0.78	-$0.93	-19.09%(-$0.15)
Q1 2026	May 7, 2026	-$0.82	-$0.79	+3.13%(+$0.03)
Q4 2025	Mar 16, 2026	-$0.74	-$0.97	-31.79%(-$0.23)
Q3 2025	Nov 4, 2025	-$0.57	-$0.65	-13.20%(-$0.08)
Q2 2025	Aug 12, 2025	-$0.54	-$0.40	+25.54%(+$0.14)

STOK Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.39

4.37

4.35

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
STOKStoke Therapeutics, Inc. Common Stock	D	F	C	56.5x	-86.2%	—	—	$24.17
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Stoke Therapeutics, Inc. Common Stock

Stoke Therapeutics develops antisense oligonucleotides (ASOs) to treat genetic diseases through its proprietary TANGO platform, which restores protein expression in haploinsufficiency disorders. The company's lead candidate, zorevunersen, has demonstrated potential for disease modification in Dravet syndrome patients. Its pipeline focuses on mutation-agnostic treatments for rare genetic disorders affecting the central nervous system and eye.

STOK Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.91

Revenue estimate$8.18M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

STOK Insider Transactions

SellSep 1, 2026
TICHO BARUCH S
Officer
Shares: 5,545Value: $170,061
SellAug 18, 2026
KAYE EDWARD M
Director
Shares: 12,567Value: $402,528
SellAug 18, 2026
TICHO BARUCH S
Officer
Shares: 4,767Value: $152,690
SellAug 18, 2026
ALLAN JONATHAN
General Counsel
Shares: 2,861Value: $91,639
SellAug 3, 2026
TICHO BARUCH S
Officer
Shares: 7,176Value: $208,385

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products
HUNHuntsman CorporationChemicals
SCLStepan Co.Soap & Detergents

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$20.32

High$40.22